Role of lipid control in diabetic nephropathy

被引:36
作者
Chen, HC [1 ]
Guh, JY [1 ]
Chang, JM [1 ]
Hsieh, MC [1 ]
Shin, SJ [1 ]
Lai, YH [1 ]
机构
[1] Kaohsiung Med Univ, Dept Internal Med, Div Nephrol & Endocrinol, Kaohsiung 807, Taiwan
关键词
lipid; diabetic nephropathy; statins;
D O I
10.1111/j.1523-1755.2005.09415.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Patients with diabetic nephropathy are known to be associated with many lipoprotein abnormalities, including higher plasma levels of very low-density lipoprotein, low-density lipoprotein and triglycerides, and lower levels of high-density lipoprotein. Many studies have reported that lipids may induce both glomerular and tubulointerstitial injury through mediators such as cytokines, reactive oxygen species, chemokines, and through hemodynamic changes. Clinical studies in patients with diabetic nephropathy showed that lipid control can be associated with an additional effect of reduction in proteinuria. Experimental studies demonstrated that lipid-lowering agents exerted a certain degree of renoprotection, through both indirect effects from lipid lowering and a direct effect on cell protection. Therefore, lipid control appears to be important in the prevention and treatment of diabetic nephropathy. Diabetic nephropathy has become the leading cause of end-stage renal failure in many countries, including Taiwan. One of the major risk factors for the development and progression of diabetic nephropathy is dyslipidemia. In this paper we will review the role of lipid in mediating renal injury and the beneficial effects of lipid control in diabetic nephropathy.
引用
收藏
页码:S60 / S62
页数:3
相关论文
共 42 条
[1]   LIPID ADVANCED GLYCOSYLATION - PATHWAY FOR LIPID OXIDATION IN-VIVO [J].
BUCALA, R ;
MAKITA, Z ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) :6434-6438
[2]   Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo [J].
Chen, HC ;
Guh, JY ;
Shin, SJ ;
Tsai, JH ;
Lai, YH .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2000, 135 (04) :309-315
[3]   Effects of pravastatin on superoxide and fibronectin production of mesangial cells induced by low-density lipoprotein [J].
Chen, HC ;
Guh, JY ;
Shin, SJ ;
Tomino, Y ;
Lai, YH .
KIDNEY & BLOOD PRESSURE RESEARCH, 2002, 25 (01) :2-6
[4]   Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose [J].
Chen, HC ;
Guh, JY ;
Shin, SJ ;
Lai, YH .
ATHEROSCLEROSIS, 2002, 160 (01) :141-146
[5]   Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with low-density lipoprotein [J].
Chen, HC ;
Guh, JY ;
Shin, SJ ;
Tsai, JH ;
Lai, YH .
KIDNEY INTERNATIONAL, 2001, 59 :S124-S127
[6]   Native and oxidized low-density lipoproteins enhance superoxide production from diabetic rat glomeruli [J].
Chen, HC ;
Tan, MS ;
Guh, JY ;
Tsai, JH ;
Lai, YH .
KIDNEY & BLOOD PRESSURE RESEARCH, 2000, 23 (02) :133-137
[7]   RELATIONSHIP BETWEEN MEVALONATE PATHWAY AND ARTERIAL MYOCYTE PROLIFERATION - IN-VITRO STUDIES WITH INHIBITORS OF HMG-COA REDUCTASE [J].
CORSINI, A ;
MAZZOTTI, M ;
RAITERI, M ;
SOMA, MR ;
GABBIANI, G ;
FUMAGALLI, R ;
PAOLETTI, R .
ATHEROSCLEROSIS, 1993, 101 (01) :117-125
[8]   3-hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy [J].
Danesh, FR ;
Sadeghi, MM ;
Amro, N ;
Philips, C ;
Zeng, LX ;
Lin, S ;
Sahai, A ;
Kanwar, YS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8301-8305
[9]   Studies of renal injury III: Lipid-induced nephropathy in type II diabetes [J].
Dominguez, JH ;
Tang, NJ ;
Xu, W ;
Evan, AP ;
Siakotos, AN ;
Agarwal, R ;
Walsh, J ;
Deeg, M ;
Pratt, JH ;
March, KL ;
Monnier, VM ;
Weiss, MF ;
Baynes, JW ;
Peterson, R .
KIDNEY INTERNATIONAL, 2000, 57 (01) :92-104
[10]   Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients [J].
Eto, M ;
Saito, M ;
Okada, M ;
Kume, Y ;
Kawasaki, F ;
Matsuda, M ;
Yoneda, M ;
Matsuki, M ;
Takigami, S ;
Kaku, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :243-251